Herantis Pharma Announces xCDNF Preclinical Candidate Selection
Herantis Pharma Plc, Company release, insider information, 31 May 2021 at 10:10 AM EEST Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, announced today that the Company has nominated HER-096 as the preclinical xCDNF candidate to take forward into further preclinical development for the treatment of Parkinson’s Disease (PD) and other neurodegenerative diseases. HER-096 was selected based on clear and compelling preclinical data including that it: · Effectively penetrates the Blood-Brain-Barrier (